Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 328

1.

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants.

Vizcardo R, Rafiqul Islam SM, Maeda T, Tamaoki N, Good ML, Klemen ND, Bosch-Marce M, Jia L, Kruhlak MJ, Restifo NP.

J Vis Exp. 2019 Aug 9;(150). doi: 10.3791/58672.

PMID:
31449236
2.

The Bone Marrow Protects and Optimizes Immunological Memory during Dietary Restriction.

Collins N, Han SJ, Enamorado M, Link VM, Huang B, Moseman EA, Kishton RJ, Shannon JP, Dixit D, Schwab SR, Hickman HD, Restifo NP, McGavern DB, Schwartzberg PL, Belkaid Y.

Cell. 2019 Aug 22;178(5):1088-1101.e15. doi: 10.1016/j.cell.2019.07.049.

PMID:
31442402
3.

Host conditioning with IL-1β improves the antitumor function of adoptively transferred T cells.

Lee PH, Yamamoto TN, Gurusamy D, Sukumar M, Yu Z, Hu-Li J, Kawabe T, Gangaplara A, Kishton RJ, Henning AN, Vodnala SK, Germain RN, Paul WE, Restifo NP.

J Exp Med. 2019 Aug 12. pii: jem.20181218. doi: 10.1084/jem.20181218. [Epub ahead of print]

PMID:
31405895
4.

Mg2+ regulation of kinase signaling and immune function.

Kanellopoulou C, George AB, Masutani E, Cannons JL, Ravell JC, Yamamoto TN, Smelkinson MG, Jiang PD, Matsuda-Lennikov M, Reilley J, Handon R, Lee PH, Miller JR, Restifo NP, Zheng L, Schwartzberg PL, Young M, Lenardo MJ.

J Exp Med. 2019 Aug 5;216(8):1828-1842. doi: 10.1084/jem.20181970. Epub 2019 Jun 13.

PMID:
31196981
5.

An effective mouse model for adoptive cancer immunotherapy targeting neoantigens.

Hanada KI, Yu Z, Chappell GR, Park AS, Restifo NP.

JCI Insight. 2019 May 16;4(10). pii: 124405. doi: 10.1172/jci.insight.124405. eCollection 2019 May 16.

6.

T cell stemness and dysfunction in tumors are triggered by a common mechanism.

Vodnala SK, Eil R, Kishton RJ, Sukumar M, Yamamoto TN, Ha NH, Lee PH, Shin M, Patel SJ, Yu Z, Palmer DC, Kruhlak MJ, Liu X, Locasale JW, Huang J, Roychoudhuri R, Finkel T, Klebanoff CA, Restifo NP.

Science. 2019 Mar 29;363(6434). pii: eaau0135. doi: 10.1126/science.aau0135.

PMID:
30923193
7.

Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.

Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, Restifo NP, Feldman SA, Lu YC, Lu L, Zheng Z, Xi L, Epstein M, McIntyre LS, Malekzadeh P, Raffeld M, Fine HA, Rosenberg SA.

J Immunother. 2019 May;42(4):126-135. doi: 10.1097/CJI.0000000000000260.

PMID:
30882547
8.

The transcription factor c-Myb regulates CD8+ T cell stemness and antitumor immunity.

Gautam S, Fioravanti J, Zhu W, Le Gall JB, Brohawn P, Lacey NE, Hu J, Hocker JD, Hawk NV, Kapoor V, Telford WG, Gurusamy D, Yu Z, Bhandoola A, Xue HH, Roychoudhuri R, Higgs BW, Restifo NP, Bender TP, Ji Y, Gattinoni L.

Nat Immunol. 2019 Mar;20(3):337-349. doi: 10.1038/s41590-018-0311-z. Epub 2019 Feb 18.

9.

Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers.

Malekzadeh P, Pasetto A, Robbins PF, Parkhurst MR, Paria BC, Jia L, Gartner JJ, Hill V, Yu Z, Restifo NP, Sachs A, Tran E, Lo W, Somerville RP, Rosenberg SA, Deniger DC.

J Clin Invest. 2019 Mar 1;129(3):1109-1114. doi: 10.1172/JCI123791. Epub 2019 Feb 4. No abstract available.

10.

Ribosomal Proteins Regulate MHC Class I Peptide Generation for Immunosurveillance.

Wei J, Kishton RJ, Angel M, Conn CS, Dalla-Venezia N, Marcel V, Vincent A, Catez F, Ferré S, Ayadi L, Marchand V, Dersh D, Gibbs JS, Ivanov IP, Fridlyand N, Couté Y, Diaz JJ, Qian SB, Staudt LM, Restifo NP, Yewdell JW.

Mol Cell. 2019 Mar 21;73(6):1162-1173.e5. doi: 10.1016/j.molcel.2018.12.020. Epub 2019 Jan 31.

PMID:
30712990
11.

T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy.

Yamamoto TN, Lee PH, Vodnala SK, Gurusamy D, Kishton RJ, Yu Z, Eidizadeh A, Eil R, Fioravanti J, Gattinoni L, Kochenderfer JN, Fry TJ, Aksoy BA, Hammerbacher JE, Cruz AC, Siegel RM, Restifo NP, Klebanoff CA.

J Clin Invest. 2019 Feb 25;129(4):1551-1565. doi: 10.1172/JCI121491. eCollection 2019 Feb 25.

12.

Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism.

Johnson MO, Wolf MM, Madden MZ, Andrejeva G, Sugiura A, Contreras DC, Maseda D, Liberti MV, Paz K, Kishton RJ, Johnson ME, de Cubas AA, Wu P, Li G, Zhang Y, Newcomb DC, Wells AD, Restifo NP, Rathmell WK, Locasale JW, Davila ML, Blazar BR, Rathmell JC.

Cell. 2018 Dec 13;175(7):1780-1795.e19. doi: 10.1016/j.cell.2018.10.001. Epub 2018 Nov 1.

PMID:
30392958
13.

Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.

Jin BY, Campbell TE, Draper LM, Stevanović S, Weissbrich B, Yu Z, Restifo NP, Rosenberg SA, Trimble CL, Hinrichs CS.

JCI Insight. 2018 Apr 19;3(8). pii: 99488. doi: 10.1172/jci.insight.99488. eCollection 2018 Apr 19.

14.

The Cish SH2 domain is essential for PLC-γ1 regulation in TCR stimulated CD8+ T cells.

Guittard G, Dios-Esponera A, Palmer DC, Akpan I, Barr VA, Manna A, Restifo NP, Samelson LE.

Sci Rep. 2018 Mar 28;8(1):5336. doi: 10.1038/s41598-018-23549-2.

15.

Generation of Tumor Antigen-Specific iPSC-Derived Thymic Emigrants Using a 3D Thymic Culture System.

Vizcardo R, Klemen ND, Islam SMR, Gurusamy D, Tamaoki N, Yamada D, Koseki H, Kidder BL, Yu Z, Jia L, Henning AN, Good ML, Bosch-Marce M, Maeda T, Liu C, Abdullaev Z, Pack S, Palmer DC, Stroncek DF, Ito F, Flomerfelt FA, Kruhlak MJ, Restifo NP.

Cell Rep. 2018 Mar 20;22(12):3175-3190. doi: 10.1016/j.celrep.2018.02.087.

16.

A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed.

Lin CC, Kurashige M, Liu Y, Terabayashi T, Ishimoto Y, Wang T, Choudhary V, Hobbs R, Liu LK, Lee PH, Outeda P, Zhou F, Restifo NP, Watnick T, Kawano H, Horie S, Prinz W, Xu H, Menezes LF, Germino GG.

Sci Rep. 2018 Feb 9;8(1):2743. doi: 10.1038/s41598-018-20856-6.

17.

Epigenetic control of CD8+ T cell differentiation.

Henning AN, Roychoudhuri R, Restifo NP.

Nat Rev Immunol. 2018 May;18(5):340-356. doi: 10.1038/nri.2017.146. Epub 2018 Jan 30. Review.

18.

Silencing stemness in T cell differentiation.

Henning AN, Klebanoff CA, Restifo NP.

Science. 2018 Jan 12;359(6372):163-164. doi: 10.1126/science.aar5541. No abstract available.

19.

Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.

Klebanoff CA, Crompton JG, Leonardi AJ, Yamamoto TN, Chandran SS, Eil RL, Sukumar M, Vodnala SK, Hu J, Ji Y, Clever D, Black MA, Gurusamy D, Kruhlak MJ, Jin P, Stroncek DF, Gattinoni L, Feldman SA, Restifo NP.

JCI Insight. 2017 Dec 7;2(23). pii: 95103. doi: 10.1172/jci.insight.95103.

20.

ASXL3 Is a Novel Pluripotency Factor in Human Respiratory Epithelial Cells and a Potential Therapeutic Target in Small Cell Lung Cancer.

Shukla V, Rao M, Zhang H, Beers J, Wangsa D, Wangsa D, Buishand FO, Wang Y, Yu Z, Stevenson HS, Reardon ES, McLoughlin KC, Kaufman AS, Payabyab EC, Hong JA, Zhang M, Davis S, Edelman D, Chen G, Miettinen MM, Restifo NP, Ried T, Meltzer PA, Schrump DS.

Cancer Res. 2017 Nov 15;77(22):6267-6281. doi: 10.1158/0008-5472.CAN-17-0570. Epub 2017 Sep 21.

21.

Identification of essential genes for cancer immunotherapy.

Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia L, Steinberg SM, Yamamoto TN, Merchant AS, Mehta GU, Chichura A, Shalem O, Tran E, Eil R, Sukumar M, Guijarro EP, Day CP, Robbins P, Feldman S, Merlino G, Zhang F, Restifo NP.

Nature. 2017 Aug 31;548(7669):537-542. doi: 10.1038/nature23477. Epub 2017 Aug 7.

22.

Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy.

Kishton RJ, Sukumar M, Restifo NP.

Cell Metab. 2017 Jul 5;26(1):94-109. doi: 10.1016/j.cmet.2017.06.016. Review.

23.

Novel "Elements" of Immune Suppression within the Tumor Microenvironment.

Gurusamy D, Clever D, Eil R, Restifo NP.

Cancer Immunol Res. 2017 Jun;5(6):426-433. doi: 10.1158/2326-6066.CIR-17-0117. Review.

24.

BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency.

Afzali B, Grönholm J, Vandrovcova J, O'Brien C, Sun HW, Vanderleyden I, Davis FP, Khoder A, Zhang Y, Hegazy AN, Villarino AV, Palmer IW, Kaufman J, Watts NR, Kazemian M, Kamenyeva O, Keith J, Sayed A, Kasperaviciute D, Mueller M, Hughes JD, Fuss IJ, Sadiyah MF, Montgomery-Recht K, McElwee J, Restifo NP, Strober W, Linterman MA, Wingfield PT, Uhlig HH, Roychoudhuri R, Aitman TJ, Kelleher P, Lenardo MJ, O'Shea JJ, Cooper N, Laurence ADJ.

Nat Immunol. 2017 Jul;18(7):813-823. doi: 10.1038/ni.3753. Epub 2017 May 22.

25.

Metabolic reprograming of anti-tumor immunity.

Sukumar M, Kishton RJ, Restifo NP.

Curr Opin Immunol. 2017 Jun;46:14-22. doi: 10.1016/j.coi.2017.03.011. Epub 2017 Apr 13. Review.

26.

Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction.

Cruz AC, Ramaswamy M, Ouyang C, Klebanoff CA, Sengupta P, Yamamoto TN, Meylan F, Thomas SK, Richoz N, Eil R, Price S, Casellas R, Rao VK, Lippincott-Schwartz J, Restifo NP, Siegel RM.

Nat Commun. 2016 Dec 23;7:13895. doi: 10.1038/ncomms13895.

27.

Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.

Slaney CY, von Scheidt B, Davenport AJ, Beavis PA, Westwood JA, Mardiana S, Tscharke DC, Ellis S, Prince HM, Trapani JA, Johnstone RW, Smyth MJ, Teng MW, Ali A, Yu Z, Rosenberg SA, Restifo NP, Neeson P, Darcy PK, Kershaw MH.

Clin Cancer Res. 2017 May 15;23(10):2478-2490. doi: 10.1158/1078-0432.CCR-16-1860. Epub 2016 Dec 13.

28.

Arginine Arms T Cells to Thrive and Survive.

Kishton RJ, Sukumar M, Restifo NP.

Cell Metab. 2016 Nov 8;24(5):647-648. doi: 10.1016/j.cmet.2016.10.019.

29.

Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers.

Wang QJ, Yu Z, Hanada KI, Patel K, Kleiner D, Restifo NP, Yang JC.

Clin Cancer Res. 2017 May 1;23(9):2267-2276. doi: 10.1158/1078-0432.CCR-16-1421. Epub 2016 Nov 1.

30.

Targeting Akt in cell transfer immunotherapy for cancer.

Crompton JG, Sukumar M, Restifo NP.

Oncoimmunology. 2015 Dec 29;5(9):e1014776. eCollection 2016.

31.

Customizing Functionality and Payload Delivery for Receptor-Engineered T Cells.

Klebanoff CA, Restifo NP.

Cell. 2016 Oct 6;167(2):304-306. doi: 10.1016/j.cell.2016.09.033.

32.

Ionic immune suppression within the tumour microenvironment limits T cell effector function.

Eil R, Vodnala SK, Clever D, Klebanoff CA, Sukumar M, Pan JH, Palmer DC, Gros A, Yamamoto TN, Patel SJ, Guittard GC, Yu Z, Carbonaro V, Okkenhaug K, Schrump DS, Linehan WM, Roychoudhuri R, Restifo NP.

Nature. 2016 Sep 22;537(7621):539-543. doi: 10.1038/nature19364. Epub 2016 Sep 14.

33.

Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche.

Clever D, Roychoudhuri R, Constantinides MG, Askenase MH, Sukumar M, Klebanoff CA, Eil RL, Hickman HD, Yu Z, Pan JH, Palmer DC, Phan AT, Goulding J, Gattinoni L, Goldrath AW, Belkaid Y, Restifo NP.

Cell. 2016 Aug 25;166(5):1117-1131.e14. doi: 10.1016/j.cell.2016.07.032.

34.

Constitutive Lck Activity Drives Sensitivity Differences between CD8+ Memory T Cell Subsets.

Moogk D, Zhong S, Yu Z, Liadi I, Rittase W, Fang V, Dougherty J, Perez-Garcia A, Osman I, Zhu C, Varadarajan N, Restifo NP, Frey AB, Krogsgaard M.

J Immunol. 2016 Jul 15;197(2):644-54. doi: 10.4049/jimmunol.1600178. Epub 2016 Jun 6.

35.

Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.

Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, Zlott DA, Yang JC, Sherry RM, Kammula US, Klebanoff CA, Hughes MS, Restifo NP, Langhan MM, Shelton TE, Lu L, Kwong ML, Ilyas S, Klemen ND, Payabyab EC, Morton KE, Toomey MA, Steinberg SM, White DE, Rosenberg SA.

J Clin Oncol. 2016 Jul 10;34(20):2389-97. doi: 10.1200/JCO.2016.66.7220. Epub 2016 May 23.

36.

BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers.

Roychoudhuri R, Clever D, Li P, Wakabayashi Y, Quinn KM, Klebanoff CA, Ji Y, Sukumar M, Eil RL, Yu Z, Spolski R, Palmer DC, Pan JH, Patel SJ, Macallan DC, Fabozzi G, Shih HY, Kanno Y, Muto A, Zhu J, Gattinoni L, O'Shea JJ, Okkenhaug K, Igarashi K, Leonard WJ, Restifo NP.

Nat Immunol. 2016 Jul;17(7):851-860. doi: 10.1038/ni.3441. Epub 2016 May 9.

37.

Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning.

Nelson MH, Bowers JS, Bailey SR, Diven MA, Fugle CW, Kaiser AD, Wrzesinski C, Liu B, Restifo NP, Paulos CM.

J Immunother Cancer. 2016 Feb 16;4:6. doi: 10.1186/s40425-016-0110-8. eCollection 2016.

38.

Acquired resistance to immunotherapy and future challenges.

Restifo NP, Smyth MJ, Snyder A.

Nat Rev Cancer. 2016 Feb;16(2):121-6. doi: 10.1038/nrc.2016.2.

39.

Prospects for gene-engineered T cell immunotherapy for solid cancers.

Klebanoff CA, Rosenberg SA, Restifo NP.

Nat Med. 2016 Jan;22(1):26-36. doi: 10.1038/nm.4015.

40.

The transcription factor BACH2 promotes tumor immunosuppression.

Roychoudhuri R, Eil RL, Clever D, Klebanoff CA, Sukumar M, Grant FM, Yu Z, Mehta G, Liu H, Jin P, Ji Y, Palmer DC, Pan JH, Chichura A, Crompton JG, Patel SJ, Stroncek D, Wang E, Marincola FM, Okkenhaug K, Gattinoni L, Restifo NP.

J Clin Invest. 2016 Feb;126(2):599-604. doi: 10.1172/JCI82884. Epub 2016 Jan 5.

41.

Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors.

Wang QJ, Yu Z, Griffith K, Hanada K, Restifo NP, Yang JC.

Cancer Immunol Res. 2016 Mar;4(3):204-14. doi: 10.1158/2326-6066.CIR-15-0188. Epub 2015 Dec 23.

42.

Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy.

Sukumar M, Liu J, Mehta GU, Patel SJ, Roychoudhuri R, Crompton JG, Klebanoff CA, Ji Y, Li P, Yu Z, Whitehill GD, Clever D, Eil RL, Palmer DC, Mitra S, Rao M, Keyvanfar K, Schrump DS, Wang E, Marincola FM, Gattinoni L, Leonard WJ, Muranski P, Finkel T, Restifo NP.

Cell Metab. 2016 Jan 12;23(1):63-76. doi: 10.1016/j.cmet.2015.11.002. Epub 2015 Dec 8.

43.

Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.

Klebanoff CA, Scott CD, Leonardi AJ, Yamamoto TN, Cruz AC, Ouyang C, Ramaswamy M, Roychoudhuri R, Ji Y, Eil RL, Sukumar M, Crompton JG, Palmer DC, Borman ZA, Clever D, Thomas SK, Patel S, Yu Z, Muranski P, Liu H, Wang E, Marincola FM, Gros A, Gattinoni L, Rosenberg SA, Siegel RM, Restifo NP.

J Clin Invest. 2016 Jan;126(1):318-34. doi: 10.1172/JCI81217. Epub 2015 Dec 14.

44.

Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance.

Palmer DC, Guittard GC, Franco Z, Crompton JG, Eil RL, Patel SJ, Ji Y, Van Panhuys N, Klebanoff CA, Sukumar M, Clever D, Chichura A, Roychoudhuri R, Varma R, Wang E, Gattinoni L, Marincola FM, Balagopalan L, Samelson LE, Restifo NP.

J Exp Med. 2015 Nov 16;212(12):2095-113. doi: 10.1084/jem.20150304. Epub 2015 Nov 2.

45.

Nutrient Competition: A New Axis of Tumor Immunosuppression.

Sukumar M, Roychoudhuri R, Restifo NP.

Cell. 2015 Sep 10;162(6):1206-8. doi: 10.1016/j.cell.2015.08.064.

46.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

47.

Enhanced T-cell activation and differentiation in lymphocytes from transgenic mice expressing ubiquitination-resistant 2KR LAT molecules.

Rodriguez-Peña AB, Gomez-Rodriguez J, Kortum RL, Palmer DC, Yu Z, Guittard GC, Wohlfert EA, Silver PB, Misplon JA, Sommers CL, Feigenbaum L, Epstein SL, Caspi RR, Belkaid Y, Restifo NP, Samelson LE, Balagopalan L.

Gene Ther. 2015 Oct;22(10):781-92. doi: 10.1038/gt.2015.48. Epub 2015 Jun 18.

48.

The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells.

Khor B, Gagnon JD, Goel G, Roche MI, Conway KL, Tran K, Aldrich LN, Sundberg TB, Paterson AM, Mordecai S, Dombkowski D, Schirmer M, Tan PH, Bhan AK, Roychoudhuri R, Restifo NP, O'Shea JJ, Medoff BD, Shamji AF, Schreiber SL, Sharpe AH, Shaw SY, Xavier RJ.

Elife. 2015 May 22;4. doi: 10.7554/eLife.05920.

49.

Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma.

Beane JD, Lee G, Zheng Z, Mendel M, Abate-Daga D, Bharathan M, Black M, Gandhi N, Yu Z, Chandran S, Giedlin M, Ando D, Miller J, Paschon D, Guschin D, Rebar EJ, Reik A, Holmes MC, Gregory PD, Restifo NP, Rosenberg SA, Morgan RA, Feldman SA.

Mol Ther. 2015 Aug;23(8):1380-1390. doi: 10.1038/mt.2015.71. Epub 2015 May 5.

50.

Lineage relationship of CD8(+) T cell subsets is revealed by progressive changes in the epigenetic landscape.

Crompton JG, Narayanan M, Cuddapah S, Roychoudhuri R, Ji Y, Yang W, Patel SJ, Sukumar M, Palmer DC, Peng W, Wang E, Marincola FM, Klebanoff CA, Zhao K, Tsang JS, Gattinoni L, Restifo NP.

Cell Mol Immunol. 2016 Jul;13(4):502-13. doi: 10.1038/cmi.2015.32. Epub 2015 Apr 27.

Supplemental Content

Loading ...
Support Center